Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03435250 · ClinicalTrials.gov registry record · Phase 1

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.

Terminated
Registry status
Phase 1
Development phase
123
Enrollment target

NCT03435250: Clinical Trial Phase 1 study, sponsored by Institut de Recherches Internationales Servier.

NCT03435250 is a Phase 1 study that was terminated before completion, run by Institut de Recherches Internationales Servier. The registered enrollment target is 123 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03435250, a Phase 1 study, was terminated before completion, sponsored by Institut de Recherches Internationales Servier.

TERMINATED
Registry status
Phase 1
Development phase
123 participants
Enrollment target

Study Summary

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.

Interventions

  • DRUG nab-paclitaxel
  • DRUG docetaxel
  • DRUG AG-270

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2018-03-04
Est. Completion 2023-04-20
Phase Phase 1

Why NCT03435250 stopped before completion

NCT03435250 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (105% higher).

The record links to 0 conditions, and to 3 interventions - of which nab-paclitaxel is the first listed.

NCT03435250 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03435250 about?

NCT03435250 is a clinical study titled "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss". This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.

What is the current status of trial NCT03435250?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2018-03-04. Estimated completion is 2023-04-20.

What interventions are being tested in trial NCT03435250?

The interventions under investigation include: nab-paclitaxel (DRUG), docetaxel (DRUG), AG-270 (DRUG).

Who is sponsoring clinical trial NCT03435250?

This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03435250's enrollment target sits among peer trials

123 475th of 2000 higher than 1,526 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05285891 · 123 participants · Phase 4

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  • NCT05334368 · 123 participants · Phase 3

    Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

  • NCT06088355 · 123 participants · NA

    Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

  • NCT06111131 · 123 participants · NA

    Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03435250, the US trial registry maintained by the National Library of Medicine. NCT03435250 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.